U.S., May 24 -- ClinicalTrials.gov registry received information related to the study (NCT06987097) titled 'Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension' on April 24.
Brief Summary: This is an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled clinical trial.
Study Start Date: May 15
Study Type: INTERVENTIONAL
Condition:
Pulmonary Arterial Hypertension (PAH)
Intervention:
DRUG: Ambrisentan
After two weeks of initial treatment, the study drugs' dose will be increased to two tablets per day (10 mg/day). If the patient cannot tolerate the increased dose (e.g., experiencing headache, dizziness, palpitations, hypotension, or other drug-related symptoms or signs), the dose will be reduced t...